Cox Capital Mgt LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,944 shares of the company’s stock after selling 825 shares during the quarter. Johnson & Johnson makes up about 2.7% of Cox Capital Mgt LLC’s investment portfolio, making the stock its 5th biggest position. Cox Capital Mgt LLC’s holdings in Johnson & Johnson were worth $3,895,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Magnolia Capital Management Ltd. increased its stake in shares of Johnson & Johnson by 0.5% during the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after buying an additional 55 shares during the period. Howard Financial Services LTD. increased its stake in shares of Johnson & Johnson by 2.1% during the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares during the period. American Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 2.1% during the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after buying an additional 57 shares during the period. Kwmg LLC increased its stake in shares of Johnson & Johnson by 2.6% during the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares during the period. Finally, Circle Wealth Management LLC increased its stake in shares of Johnson & Johnson by 0.5% during the first quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after buying an additional 59 shares during the period. 68.59% of the stock is owned by institutional investors.
Johnson & Johnson Stock Up 1.5 %
Johnson & Johnson stock opened at $167.60 on Monday. The stock has a market capitalization of $440.65 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 2.99 and a beta of 0.61. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The business has a 50 day simple moving average of $168.96 and a 200-day simple moving average of $174.29. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17.
Johnson & Johnson announced that its Board of Directors has approved a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.
Analyst Ratings Changes
Several equities analysts have issued reports on JNJ shares. Citigroup cut their target price on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. SVB Leerink lowered their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley lowered their price target on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a report on Monday, September 12th. UBS Group decreased their target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Wells Fargo & Company lifted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $189.78.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.